Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Year: 2025
Type: other
Abstract: Dual targeting of Bcl-xL and Mcl-1 leads to synergistic decreases in cell viability in 3D LNCaP95 spheroids and the LuCaP 167CR organoid model. Dual treatment of navitoclax and A-1331852 with S63845 in 3D prostate cancer models. A, Representative images for each treatment condition before treatment and 24, 48, and 72 hours after treatment. B and C, Viability of spheroids measured by 3D CellTiter-Glo after 72 hours of treatment. Plots show mean ± SD. ****, P < 0.0001. LuCaP-167CR organoids were treated with the combination of A-1331852 and S63845 (D–F) or navitoclax and S63845 (G–I). Drug curves (D and G) show mean ± SD. Dose–response matrices (E and H) and Bliss synergy plots (F and I) were generated using the Synergyfinder+ R package to evaluate synergy. All spheroid experiments were completed in triplicate. Organoid experiments had six technical replicates with three biological replicates.
Authors: Benjamin C. Brim, Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang, Giulia C. Napoli, Emily N. Risdon, Keith T. Schmidt, Kelli M. Wilson, Crystal McKnight, Erin Beck, Carleen Klumpp-Thomas, Michele Ceribelli, JuanJuan Yin, Adam G. Sowalsky, Douglas K. Price, Cindy H. Chau, Craig J. Thomas, William D. Figg
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4413370028